

# Chronic mesenteric ischemia: clinical outcome after endovascular therapy

Manuela Matschuck MD

University hospital Leipzig

# Disclosure

Speaker name:

Manuela Matschuck MD

I have the following potential conflicts of interest to report:

- Consulting
- Employment in industry
- Stockholder of a healthcare company
- Owner of a healthcare company
- Other(s)
  
- I do not have any potential conflict of interest

# Demographic

Demographics and Clinical features at baseline	Number/Total (%) or mean±SD
<b>Patient Demographics</b>	
<b>Gender</b>	
Male	10/25 (40%)
Female	15/25 (60%)
<b>Age (years)</b>	70,1 ± 10,1
<b>Weight (kg)</b>	63,2 ± 10,5
<b>Comorbidities</b>	
Diabetes	9/25 (36%)
<b>Smoking (previous or current)</b>	16/25 (64%)
Dyslipidemia	18/25 (72%)
<b>Hypertension</b>	24/24 (100%)
Atrial fibrillation	10/24 (41,7%)
Coronary artery disease	08/25 (32%)
Chronic heart failure (NYHA II and III)	04/24 (16.7%)
Cerebrovascular disease	10/25 (40%)
Chronic renal insufficiency (grade 2-5)	10/25 (40%)
<b>Peripheral artery disease at the lower limb</b>	16/24 (66,7%)
<b>Colitis</b>	16/25 (64%)
Gastric ulcera	05/25 (20%)
<b>Etiology</b>	
Atherosclerosis	24/25 (96%)
Thrombotic	0
Dunbar Syndrom	0
Unknown	1/25 (4%)
<b>Symptoms</b>	
Loss of weight	11/25 (44%)
Postprandial pain	14/25 (56%)
Inappetence	4/25 (16%)
Nausea	7/25 (28%)
Asymptomatic	2/25 (8%)
<b>Baseline blood pressure in mmHg</b>	
Systolic left arm	145,1 ± 20,4
Diastolic left arm	77,8 ± 20,8
<b>Time from Symptoms to diagnose (month)</b>	2,7 ± 1,2
<b>Diagnostic</b>	
Duplex Ultrasound	7/25 (28%)
Angiography	3/25 (12%)
CT	17/25 (68%)
MRI	3/25 (12%)


# Angiographic Features

Angiographic Features at Baseline	Number/Total (%) or mean±SD
<b>Treated vessel</b>	
Celiac Trunk	05/25 (20%)
Superior mesenteric artery	<b>20/25 (80%)</b>
Inferior mesenteric artery	02/25 (8%)
<b>Lesion characteristics</b>	
Lesion length (cm)	2,0±1,1
Lesion diameter (cm)	0,9±0,6
Chronic total occlusion	4/25 (16%)
Stenosis (%)	87,3±9,6
<b>Calcification</b>	
none	0/25
little	9/25 (36%)
moderate	8/25 (32%)
severe	8/25 (32%)
<b>1 vessel treated</b>	24/25 (96%)
<b>&gt;1 vessel treated</b>	1/25 (4%)



# Intervention Features

Intervention Features	Number/Total (%) or mean±SD
<b>Successful intervention</b>	25/25 (100%)
Residual stenosis (>30%)	1/25 (4%)
Complete total occlusion (CTO)	4/25 (16%)
<b>Stent type</b>	
BMS (Balloon-expandable)	12/25 (48%)
BMS (Self-expandable)	03/25 (12%)
DES	0/25 (0%)
Covered Stent	7/25 (28%)
<b>SMA</b>	
Stent length (mm)	26 ± 11
Stent diameter (mm)	6,8±0,7
<b>CT</b>	
Stent length (mm)	25,4±9,5
Stent diameter (mm)	7,7±0,9
<b>Complications</b>	0
<b>Radiation</b>	
Fluoroscopy time (min)	20,9±12,4

# Primary Patency





# Comparison SMA vs. CT



SMA... Superior Mesenteric Artery  
CT...Celiac Trunk

# Comparison BMS vs. Covered Stent



BMS...Bare Metal Stent



# Conclusions



- Think of it!!
- Endovascular approach is safe and feasible
- Prefer balloon-expandable stents (BMS) or covered stents



# Chronic mesenteric ischemia: clinical outcome after endovascular therapy

Manuela Matschuck MD

University hospital Leipzig